Tazeen Ahmad of B of A Securities, Downgraded "Ascendis Pharma A/S" (ASND) to Hold and Increased Target from $164 to $169 on, Oct 20th, 2021.

Tazeen has made no other calls on ASND in the last 4 months.

There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 0 agree with Tazeen's Rating of Hold.

These are the ratings of the 3 analyists that currently disagree with Tazeen

David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $204 on, Thursday, August 26th, 2021
Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $182 on, Thursday, August 26th, 2021
Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $185 on, Thursday, August 26th, 2021